Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 28
Summary
- Conditions
- Colon Cancer
- Colorectal Cancer
- Metastatic Colorectal Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Regorafenib and NivolumabMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03712943
- Collaborators
- Bristol-Myers Squibb
- Investigators
- Principal Investigator: Dae W Kim, MD H. Lee Moffitt Cancer Center and Research Institute
Get Well Soon